Browse AP2S1

Summary
SymbolAP2S1
Nameadaptor-related protein complex 2, sigma 1 subunit
Aliases FBHOk; FBH3; CLAPS2; HHC3; hypocalciuric hypercalcemia 3 (Oklahoma type); AP17; HA2 17 kDa subunit; adaptor ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane. Membrane, coated pit; Peripheral membrane protein; Cytoplasmic side. Note=AP-2 appears to be excluded from internalizing CCVs and to disengage from sites of endocytosis seconds before internalization of the nascent CCV.
Domain PF01217 Clathrin adaptor complex small chain
Function

Component of the adaptor protein complex 2 (AP-2). Adaptor protein complexes function in protein Transport via Transport vesicles in different membrane traffic pathways. Adaptor protein complexes are vesicle coat components and appear to be involved in cargo selection and vesicle formation. AP-2 is involved in clathrin-dependent endocytosis in which cargo proteins are incorporated into vesicles surrounded by clathrin (clathrin-coated vesicles, CCVs) which are destined for fusion with the early endosome. The clathrin lattice serves as a mechanical scaffold but is itself unable to bind directly to membrane components. Clathrin-associated adaptor protein (AP) complexes which can bind directly to both the clathrin lattice and to the lipid and protein components of membranes are considered to be the major clathrin adaptors contributing the CCV formation. AP-2 also serves as a cargo receptor to selectively sort the membrane proteins involved in receptor-mediated endocytosis. AP-2 seems to play a role in the recycling of synaptic vesicle membranes from the presynaptic surface. AP-2 recognizes Y-X-X-[FILMV] (Y-X-X-Phi) and [ED]-X-X-X-L-[LI] endocytosis signal motifs within the cytosolic tails of transmembrane cargo molecules. AP-2 may also play a role in maintaining normal post-endocytic trafficking through the ARF6-regulated, non-clathrin pathway. The AP-2 alpha and AP-2 sigma subunits are thought to contribute to the recognition of the [ED]-X-X-X-L-[LI] motif (By similarity). May also play a role in extracellular calcium homeostasis.

> Gene Ontology
 
Biological Process GO:0001736 establishment of planar polarity
GO:0001738 morphogenesis of a polarized epithelium
GO:0002478 antigen processing and presentation of exogenous peptide antigen
GO:0002495 antigen processing and presentation of peptide antigen via MHC class II
GO:0002504 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II
GO:0002697 regulation of immune effector process
GO:0002831 regulation of response to biotic stimulus
GO:0006898 receptor-mediated endocytosis
GO:0007018 microtubule-based movement
GO:0007164 establishment of tissue polarity
GO:0007173 epidermal growth factor receptor signaling pathway
GO:0009615 response to virus
GO:0016055 Wnt signaling pathway
GO:0019882 antigen processing and presentation
GO:0019884 antigen processing and presentation of exogenous antigen
GO:0019886 antigen processing and presentation of exogenous peptide antigen via MHC class II
GO:0030100 regulation of endocytosis
GO:0035567 non-canonical Wnt signaling pathway
GO:0038127 ERBB signaling pathway
GO:0042058 regulation of epidermal growth factor receptor signaling pathway
GO:0042059 negative regulation of epidermal growth factor receptor signaling pathway
GO:0043900 regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0048002 antigen processing and presentation of peptide antigen
GO:0048013 ephrin receptor signaling pathway
GO:0048268 clathrin coat assembly
GO:0050688 regulation of defense response to virus
GO:0050690 regulation of defense response to virus by virus
GO:0050792 regulation of viral process
GO:0051607 defense response to virus
GO:0060071 Wnt signaling pathway, planar cell polarity pathway
GO:0060627 regulation of vesicle-mediated transport
GO:0072583 clathrin-dependent endocytosis
GO:0090175 regulation of establishment of planar polarity
GO:0098542 defense response to other organism
GO:0198738 cell-cell signaling by wnt
GO:1901184 regulation of ERBB signaling pathway
GO:1901185 negative regulation of ERBB signaling pathway
GO:1905330 regulation of morphogenesis of an epithelium
GO:2000027 regulation of organ morphogenesis
Molecular Function GO:0008565 protein transporter activity
GO:0030276 clathrin binding
GO:0030674 protein binding, bridging
GO:0035615 clathrin adaptor activity
GO:0060090 binding, bridging
GO:0098748 endocytic adaptor activity
Cellular Component GO:0005765 lysosomal membrane
GO:0005905 clathrin-coated pit
GO:0010008 endosome membrane
GO:0030117 membrane coat
GO:0030118 clathrin coat
GO:0030119 AP-type membrane coat adaptor complex
GO:0030120 vesicle coat
GO:0030122 AP-2 adaptor complex
GO:0030125 clathrin vesicle coat
GO:0030128 clathrin coat of endocytic vesicle
GO:0030131 clathrin adaptor complex
GO:0030132 clathrin coat of coated pit
GO:0030135 coated vesicle
GO:0030136 clathrin-coated vesicle
GO:0030139 endocytic vesicle
GO:0030659 cytoplasmic vesicle membrane
GO:0030662 coated vesicle membrane
GO:0030665 clathrin-coated vesicle membrane
GO:0030666 endocytic vesicle membrane
GO:0030669 clathrin-coated endocytic vesicle membrane
GO:0036019 endolysosome
GO:0036020 endolysosome membrane
GO:0044440 endosomal part
GO:0045334 clathrin-coated endocytic vesicle
GO:0048475 coated membrane
GO:0098589 membrane region
GO:0098852 lytic vacuole membrane
> KEGG and Reactome Pathway
 
KEGG hsa04144 Endocytosis
hsa04721 Synaptic vesicle cycle
hsa04961 Endocrine and other factor-regulated calcium reabsorption
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-422475: Axon guidance
R-HSA-3858494: Beta-catenin independent WNT signaling
R-HSA-8856825: Cargo recognition for clathrin-mediated endocytosis
R-HSA-8856828: Clathrin-mediated endocytosis
R-HSA-1266738: Developmental Biology
R-HSA-1643685: Disease
R-HSA-2682334: EPH-Ephrin signaling
R-HSA-3928665: EPH-ephrin mediated repulsion of cells
R-HSA-399721: Glutamate Binding, Activation of AMPA Receptors and Synaptic Plasticity
R-HSA-162906: HIV Infection
R-HSA-162909: Host Interactions of HIV factors
R-HSA-168256: Immune System
R-HSA-5663205: Infectious disease
R-HSA-373760: L1CAM interactions
R-HSA-171052: LDL-mediated lipid transport
R-HSA-73923: Lipid digestion, mobilization, and transport
R-HSA-174824: Lipoprotein metabolism
R-HSA-2132295: MHC class II antigen presentation
R-HSA-199991: Membrane Trafficking
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-187037: NGF signalling via TRKA from the plasma membrane
R-HSA-167590: Nef Mediated CD4 Down-regulation
R-HSA-182218: Nef Mediated CD8 Down-regulation
R-HSA-164938: Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters
R-HSA-112316: Neuronal System
R-HSA-112314: Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
R-HSA-4086400: PCP/CE pathway
R-HSA-437239: Recycling pathway of L1
R-HSA-177504: Retrograde neurotrophin signalling
R-HSA-162582: Signal Transduction
R-HSA-195721: Signaling by Wnt
R-HSA-166520: Signalling by NGF
R-HSA-164952: The role of Nef in HIV-1 replication and disease pathogenesis
R-HSA-399719: Trafficking of AMPA receptors
R-HSA-416993: Trafficking of GluR2-containing AMPA receptors
R-HSA-112315: Transmission across Chemical Synapses
R-HSA-8855121: VLDL interactions
R-HSA-8866427: VLDLR internalisation and degradation
R-HSA-5653656: Vesicle-mediated transport
R-HSA-5140745: WNT5A-dependent internalization of FZD2, FZD5 and ROR2
R-HSA-5099900: WNT5A-dependent internalization of FZD4
Summary
SymbolAP2S1
Nameadaptor-related protein complex 2, sigma 1 subunit
Aliases FBHOk; FBH3; CLAPS2; HHC3; hypocalciuric hypercalcemia 3 (Oklahoma type); AP17; HA2 17 kDa subunit; adaptor ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between AP2S1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolAP2S1
Nameadaptor-related protein complex 2, sigma 1 subunit
Aliases FBHOk; FBH3; CLAPS2; HHC3; hypocalciuric hypercalcemia 3 (Oklahoma type); AP17; HA2 17 kDa subunit; adaptor ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of AP2S1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.59 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolAP2S1
Nameadaptor-related protein complex 2, sigma 1 subunit
Aliases FBHOk; FBH3; CLAPS2; HHC3; hypocalciuric hypercalcemia 3 (Oklahoma type); AP17; HA2 17 kDa subunit; adaptor ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of AP2S1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0420.888
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3170.926
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.1640.946
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.0160.967
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.2990.843
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3460.863
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.4130.336
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.6090.728
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2310.907
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0280.99
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.2430.943
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0680.348
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of AP2S1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolAP2S1
Nameadaptor-related protein complex 2, sigma 1 subunit
Aliases FBHOk; FBH3; CLAPS2; HHC3; hypocalciuric hypercalcemia 3 (Oklahoma type); AP17; HA2 17 kDa subunit; adaptor ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of AP2S1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolAP2S1
Nameadaptor-related protein complex 2, sigma 1 subunit
Aliases FBHOk; FBH3; CLAPS2; HHC3; hypocalciuric hypercalcemia 3 (Oklahoma type); AP17; HA2 17 kDa subunit; adaptor ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of AP2S1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by AP2S1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolAP2S1
Nameadaptor-related protein complex 2, sigma 1 subunit
Aliases FBHOk; FBH3; CLAPS2; HHC3; hypocalciuric hypercalcemia 3 (Oklahoma type); AP17; HA2 17 kDa subunit; adaptor ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of AP2S1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolAP2S1
Nameadaptor-related protein complex 2, sigma 1 subunit
Aliases FBHOk; FBH3; CLAPS2; HHC3; hypocalciuric hypercalcemia 3 (Oklahoma type); AP17; HA2 17 kDa subunit; adaptor ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of AP2S1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolAP2S1
Nameadaptor-related protein complex 2, sigma 1 subunit
Aliases FBHOk; FBH3; CLAPS2; HHC3; hypocalciuric hypercalcemia 3 (Oklahoma type); AP17; HA2 17 kDa subunit; adaptor ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between AP2S1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolAP2S1
Nameadaptor-related protein complex 2, sigma 1 subunit
Aliases FBHOk; FBH3; CLAPS2; HHC3; hypocalciuric hypercalcemia 3 (Oklahoma type); AP17; HA2 17 kDa subunit; adaptor ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting AP2S1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.